These include studies demonstrating the effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with renal disease [16] and reports showing improvements in postprandial hyperglycemia with nateglinide and/or acarbose in patients with rheumatoid arthritis or collagen diseases [17]. Here, DPP4 is linked to rheumatoid arthritis.